We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
News

AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition

AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
News

AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AVEO Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office granted to AVEO U.S. Patent No. 7,544,476.

This patent covers the use of the expression level of a single gene, HeyL, as a predictive biomarker to identify human tumors that are likely to respond to treatment with inhibitors of the Notch pathway, thus adding to the intellectual property surrounding AVEO’s proprietary and translational biology platform.

“The discovery of HeyL as a biomarker of sensitivity to Notch pathway inhibitors will greatly facilitate AVEO’s program to develop monoclonal antibodies targeting the Notch pathway in cancer,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO Pharmaceuticals. “The development of improved diagnostics based on the discovery of biomarkers has the potential to accelerate new drug development by identifying, in advance, responsive patients, thus realizing the vision of the company.”

The Notch pathway is widely recognized as a potential therapeutic target in the treatment of certain cancers, and is a key regulator of angiogenesis and cancer stem cells. However, the complexity of Notch biology makes the effect of Notch inhibition in any given tumor very difficult to predict. Therefore, the identification of a predictive biomarker is a critical step in the development of any therapeutic agent targeting Notch signaling in cancer.

To this end, AVEO researchers have identified key differences in expression of Notch pathway target genes between human cancer cell lines that were either sensitive or resistant to small molecule and biologic inhibitors of the Notch pathway.

AVEO discovered that the expression of a single gene, known as HeyL, was predictive of sensitivity of human cancer cell lines to Notch pathway inhibition. Moreover, HeyL expression similarly correlated with Notch-dependence in vivo in a mouse model of cancer.
Advertisement